This week, Redwire is gearing up for a monumental milestone on orbit that could have important implications for human health on Earth.
The Redwire team is initiating operations for the BFF-Meniscus-2 investigation, which will use Redwire’s upgraded BioFabrication Facility (BFF) on the International Space Station (ISS) to bioprint a human knee meniscus. The investigation is exploring how space bioprinting could help treat meniscal injuries, one of the most common orthopedic injuries affecting U.S. military service members. The print will be the first time a full human knee meniscus is bioprinted in space.
Once BFF prints the meniscus with living human cells in the bioinks, it will be transferred to Redwire’s Advanced Space Experiment Processor (ADSEP) to be cultured for 14 days to produce the solidified meniscus. The meniscus will then be stored for return and analysis back on Earth. BFF-Meniscus-2 builds on a 2019 experiment where the BFF 3D printed a meniscus-shaped scaffold using bioink derived from human tissue proteins. However, no living cells were included.
For BFF-Meniscus-2, Redwire is working with the Uniformed Services University of the Health Sciences Center for Biotechnology (4DBio3), a biomedical research center that explores and adapts promising biotechnologies for warfighter benefit.
As a permanent fixture to the ISS, BFF is enabling game-changing opportunities in biomedical and pharmaceutical research to benefit human health on Earth. BFF is part of Redwire’s growing portfolio of technologies and innovative on-orbit capabilities enabling human spaceflight missions and commercial microgravity research and development in low-Earth orbit.
Follow Redwire on social media for updates on the BFF-Meniscus-2 investigation.
Watch this video to learn more about BFF and see it being installed on the ISS earlier this year:
